Please login to order a test.
- Dihydropyrimidine Dehydrogenase
Variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (DPD).
This procedure will only detect the presence of the wild type or mutant allele for the DPD IVS14+1G>A mutation.
Polymerase chain reaction (PCR); restriction enzyme digestion; gel electrophoresis
DPD deficiency results in excessive amounts of 5-FU available to be anabolized to its active metabolite and is relatively undetectable by clinical observation prior to 5-FU administration. Extensive studies have associated both profound and partial deficiency in DPD activity with severe unanticipated toxicity after 5-FU administration. Numerous studies genotyping DPD deficient patients, their family members, and healthy individuals have shown that the splice-site mutation (IVS14+1G>A) is the most characterized and frequently observed allele associated with decreased DPD enzyme activity. Screening for the presence of this mutation in the Caucasian population showed frequencies of 0.91% homozygous and 1.8% heterozygous for the IVS14+1G>A allele.
Whole blood or LabCorp buccal swab kit (buccal swab collection kit contains instructions for use of a buccal swab)
7 mL whole blood or LabCorp buccal swab kit
3 mL whole blood or two buccal swabs
Causes for Rejection
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|511176||DPD 5-Fluorouracil Toxicity||511186||Result:||45284-7|
|511176||DPD 5-Fluorouracil Toxicity||511235||Mutation:||N/A|
|511176||DPD 5-Fluorouracil Toxicity||511189||Director Review:||72486-4|